Please assess the completion status of the following clinical trial:

Trial Title: Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent~* Age ≥ 18 years~* Histologically-confirmed adenocarcinoma of the prostate~* Hormone-refractory prostate cancer~* Failed 1st-line docetaxel-containing regimen~* No prior immunotherapy including:~  * Vaccines~ * GM-CSF~* Minimum prostate-specific antigen (PSA) \> 5 mg/dL and rising according to the PSA Consensus Criteria~* Karnofsky Performance Status (KPS) \> 60%~* Eastern Cooperative Oncology Group (ECOG) Performance Status \< 3~* Life expectancy \> 6 months~Exclusion Criteria:~* Concomitant hormonal therapy other than luteinizing hormone-releasing hormone (LHRH) agonist~* Use of herbal products known to decrease PSA levels~* Use of supplements or complementary medicines, except for:~  * Conventional multivitamin supplements~ * Selenium~ * Lycopene~ * Soy supplements~ * Vitamin E~* Initiation of bisphosphonates within one month prior to enrollment or throughout the study~* Any prior radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment~* Major surgery or radiation therapy completed \< 4 weeks prior to enrollment~* Any concomitant second malignancy other than non-melanoma skin cancer~* Any concomitant serious infection~* Any nonmalignant medical illness~* Absolute neutrophil count (ANC) \< 1,500/µL~* Platelet count \< 100,000 µL~* Hemoglobin \< 8 mg/dL~* Total bilirubin greater than 1.5 x upper limit of normal (ULN)~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2.5 x ULN if no demonstrable liver metastases, or greater than 5.0 x ULN in presence of liver metastases~* Ejection fraction \< 50% as measured by echocardiogram (ECHO) or multigated acquisition (MUGA) scan~* Noncompliance with study procedures

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- GM-CSF Plus Mitoxantrone (Type: EXPERIMENTAL): GM-CSF at 250 micrograms/ m² / day subcutaneously 3 x week for 3 weeks. Participants will also receive mitoxantrone 14 mg/m² on Day 1 of each cycle. Each cycle of therapy consists 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).